Prothena Corporation plc: Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference

DUBLIN, Ireland, 2017-11-22 22:05 CET (GLOBE NEWSWIRE) --
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology
company focused on the discovery, development and commercialization of novel
therapies in the neuroscience and orphan arenas, today announced that members
of its senior management team will present and participate in the Evercore ISI
Biopharma Catalyst/Deep Dive Conference on November 30th at 1:15 PM ET in
Boston, MA. 

A live webcast of the company presentation can be accessed through the investor
relations section of the Company's website at www.prothena.com. Following the
live presentation, a replay of the webcast will be available on the Company's
website for at least 90 days following the presentation date. 

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
establishing fully integrated research, development and commercial capabilities
and focused on advancing new therapies in the neuroscience and orphan arenas.
Fueled by its deep scientific understanding built over decades of research in
protein misfolding, Prothena seeks to fundamentally change the course of grave
or currently untreatable diseases associated with this biology. Prothena's
pipeline of antibody therapeutic candidates targets a number of indications
including AL amyloidosis (NEOD001), Parkinson's disease and other related
synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company
continues discovery of additional novel therapeutic candidates where its deep
scientific understanding of disease pathology can be leveraged. For more
information, please visit the Company's website at www.prothena.com. 

Media & Investor Contact:

Ellen Rose, Head of Communications
650-922-2405, [e-mail]